Blockade of the renin-angiotensin-aldosterone system: A key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 11-25

  Burnier, Michel ^a   Zanchi, Anne ^a  

^a Division de Néphrologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ALBUMINURIA; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DIZZINESS; DRUG TOLERABILITY; DYSLIPIDEMIA; HEALTH CARE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; STROKE; SURVIVAL; THORAX PAIN; VERTIGO;

EID: 29144521901     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000191244.91314.9d     Document Type: Review

References (183)

1. Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med 2002; 19(Suppl 4):1-5.
2. Dunstan DW, Zimmet PZ, Welborn TA, de Court, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25:829-834.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
4. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76-79.
5. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100:1134-1146.
6. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II - editorial review. Curr Opin Nephrol Hypertens 2005; 14:125-131.
7. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-259.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
11. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
12. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl 1):S1-S147.
13. US Renal Data System. USRDS 2000 annual data report, Section A. Incidence of reported ESRD. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000. pp. 249-293.
14. Valderrabano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10(Suppl 5):1-25.
15. Earle KK, Porter KA, Ostberg J, Yudkin JS. Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant 2001; 16:286-290.
16. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994; 9:1097-1102.
17. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74:1143-1155.
18. Steffes MW, Bilous RW, Sutherland DE, Mauer SM. Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 1992; 41:679-684.
19. 9 Mauer SM, Mogensen CE, Friedman E. Diabetic nephropathy. In: Schrier RW, Gottschalk CW, editors. Diseases of the kidney. New York: Little, Brown & Co.; 1996. pp. 2019-2062.
20. Dalla VM, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000; 26(Suppl 4):8-14.
21. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
22. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
23. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-1444.
24. Andersen NH, Knudsen ST, Poulsen PL, Poulsen SH, Helleberg K, Eiskjaer H, et al. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design. J Renin Angiotensin Aldosterone Syst 2003; 4:96-99.
25. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16(Suppl 1):85-89.
26. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961.
27. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310:356-360.
28. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988; 5:126-134.
29. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25:107-112.
30. Fioretto P, Steffes MW, Sutherland DE, Mauer M. Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression. Kidney Int 1995; 48:1929-1935.
31. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994; 43:1358-1364.
32. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 1993; 3:1458-1466.
33. Gellman DD, Pirani CL, Soothill JF, Muehrcke RC, Maduros W, Kark RM. Structure and function in diabetic nephropathy; the importance of diffuse glomerulosclerosis. Diabetes 1959; 8:251-256.
34. Kahn S, Seghal V, Appel GB, D'Agati V. Correlates of diabetic and nondiabetic renal lesion in NIDDM [abstract]. J Am Soc Nephrol 1995; 6:451.
35. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993; 43:661-667.
36. Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41:758-762.
37. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29:153-163.
38. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-2437.
39. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE. Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994; 45:177-184.
40. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77:393-S98.
41. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992; 140:95-107.
42. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265:F477-F486.
43. Kikkawa R, Kitamura E, Fujiwara Y, Haneda M, Shigeta Y. Biphasic alteration of renin-angiotensin-aldosterone system in streptozotocin-diabetic rats. Ren Physiol 1986; 9:187-192.
44. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994; 45:403-410.
45. De'Oliveira JM, Price DA, Fisher ND, Allan DR, McKnight JA, Williams GH, et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997; 52:771-777.
46. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995; 26:602-609.
47. Hollenberg NK. ACE inhibitors, AT1 receptor blockers, and the kidney. Nephrol Dial Transplant 1997; 12:381-383.
48. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002; 25:1909-1913.
49. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17:72-80.
50. de Pablos PL, Martinez FJ. Effects of losartan and diltiazem on blood pressure, insulin sensitivity, lipid profile, and microalbuminuria in hypertensive type 2 diabetic patients. Clin Drug Invest 1998; 16:361-370.
51. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16(Suppl 1):90-93.
52. Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care 2002; 25:663-671.
53. Kavgaci H, Sahin A, Onder EH, Erem C, Ozdemir F. The effects of losartan and fosinopril in hypertensive type 2 diabetic patients. Diabetes Res Clin Pract 2002; 58:19-25.
54. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58:762-769.
55. Pablos-Velasco PL, Pazos TF, Esmatjes JE, Fernandez-Vega F, Lopez de la Torre ML, Pozuelo A, et al. Losartan titration versus diuretic combination in type 2 diabetic patients. J Hypertens 2002; 20:715-719.
56. Tan KC, Chow WS, Ai VH, Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev 2002; 18:71-76.
57. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139:90-96.
58. The BErgamo NEphrologic Diabetes Complications Trial (BENEDICT): design and baseline characteristics. Control Clin Trials 2003; 24:442-461.
59. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951.
60. Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, et al. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Kidney Int Suppl 2002; 82:64-67.
61. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163:1555-1565.
62. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002; 17:1413-1418.
63. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109:2492-2499.
64. Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 2001; 38:157-161.
65. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26:2268-2274.
66. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28:273-277.
67. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003; 41:31-36.
68. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-1297.
69. Kannel WB, McGee DL Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59:8-13.
70. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151:1141-1147.
71. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Rieber GE, Bennett PH, editors. Diabetes in America. Bethesda, MD: National Institutes of Health; 1995. pp. 429-448.
72. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. Br Med J 1998; 317:720-726.
73. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255-3264.
74. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-419.
75. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276:1886-1892.
76. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
77. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35:985-991.
78. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000; 97:931-936.
79. Iwami K, Ashizawa N, Do YS, Graf K, Hsueh WA. Comparison of ANG II with other growth factors on Egr-1 and matrix gene expression in cardiac fibroblasts. Am J Physiol 1996; 270:H2100-H2107.
80. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25:913-917.
81. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
82. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90:456-461.
83. Touyz RM, He G, Deng LY, Schiffrin EL. Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance arteries. Circulation 1999; 99:392-399.
84. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33:1399-1405.
85. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226:862-868.
86. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999; 33:335-339.
87. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138:542-549.
88. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32:1454-1459.
89. Knutsen R, Knutsen SF, Curb JD, Reed DM, Kautz JA, Yano K. The predictive value of resting electrocardiograms for 12-year incidence of coronary heart disease in the Honolulu Heart Program. J Clin Epidemiol 1988; 41:293-302.
90. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
91. MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, et al. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1989; 63:202-210.
92. Sullivan JM, Vander Zwaag RV, el Zeky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol 1993; 22:508-513.
93. Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77:18-22.
94. Hess OM, Schneider J, Koch R, Bamert C, Grimm J, Krayenbuehl HP. Diastolic function and myocardial structure in patients with myocardial hypertrophy. Special reference to normalized viscoelastic data. Circulation 1981; 63:360-371.
95. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990; 3:735-740.
96. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52:11-34.
97. Lijnen P, Petrov V. Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Methods Find Exp Clin Pharmacol 1999; 21:363-374.
98. Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002; 89:562-566.
99. Scott-Burden T, Hahn AW, Resink TJ, Buhler FR. Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. J Cardiovasc Pharmacol 1990; 16(Suppl 4):S36-S41.
100. Hafizi S, Wharton J, Morgan K, Allen SP, Chester AH, Catravas JD, et al. Expression of functional angiotensin-converting enzyme and AT1 receptors in cultured human cardiac fibroblasts. Circulation 1998; 98:2553-2559.
101. Ju H, Zhao S, Jassal DS, Dixon IM. Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 1997; 35:223-232.
102. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 1996; 118:549-556.
103. Gonzalez BL, Kurnjek ML, Muller A, Basso N. Effect of chronic angiotensin II inhibition on the cardiovascular system of the normal rat. Am J Hypertens 2000; 13:1301-1307.
104. Sandmann S, Yu M, Unger T. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction - effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor. Br J Pharmacol 2001; 132:767-777.
105. Thai HM, Van HT, Gaballa MA, Goldman S, Raya TE. Effects of AT1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am J Physiol 1999; 276:H873-H880.
106. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17:107-114.
107. Varo N, Iraburu MJ, Varela M, Lopez L, Etayo JC, Diez J. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35:1197-1202.
108. Yu G, Liang X, Xie X, Yang T, Sun M, Zhao S. Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan. Chin Med J (Engl) 2002; 115:1287-1291.
109. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512-2517.
110. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-291.
111. Avanza AC Jr, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq Bras Cardiol 2000; 74:103-117.
112. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
113. De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16:133-140.
114. Linz W, Gohlke P, Unger T, Scholkens BA. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Coeur Vaiss 1995; 88(Spec No 2):31-34.
115. Maia LN, Nicolau JC, Vitola JV, Santos M, Brandi JM, Joaquim MR, et al. Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. Am Heart J 2003; 145:E21.
116. Martina B, Dieterle T, Weinbacher M, Battegay E. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology 1999; 92:110-114.
117. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, et al. Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) 2003; 104:109-118.
118. Rials SJ, Xu X, Wu Y, Liu T, Marinchack RA, Kowey PR. Restoration of normal ventricular electrophysiology in renovascular hypertensive rabbits after treatment with losartan. J Cardiovasc Pharmacol 2001; 37:317-323.
119. Tedesco MA, Ratti G, Aquino D, Limongelli G, Di Salvo G, Mennella S, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12:505-510.
120. Yang YJ, Tang YD, Ruan YM, Zhang P, Zhou YW, Wang PH, et al. Comparative effects of carvedilol and losartan alone and in combination for preventing left ventricular remodeling after acute myocardial infarction in rats. Circ J 2003; 67:159-162.
121. Zhang G, Shen X, Pu S, Yang Y, Pan W, Chen H. Comparative effects of losartan and captopril on ventricular remodeling and function after myocardial infarction in the rat. Chin Med Sci J 1998; 13:32-36.
122. Zornoff LA, Matsubara LS, Matsubara BB, Paiva SA, Spadaro J. Effects of losartan on ventricular remodeling in experimental infarction in rats. Arq Bras Cardiol 2000; 75:459-470.
123. Brilla CG, Scheer C, Rupp H. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin Il type 1 receptor antagonism. J Hypertens Suppl 1997; 15:S13-S19.
124. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999; 10(Suppl 11): S143-S148.
125. Hara K, Kobayashi N, Nakano S, Mori Y, Tsubokou Y, Matsuoka H. Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats. Hypertens Res 2001; 24:55-64.
126. Ikeda Y, Nakamura T, Takano H, Kimura H, Obata JE, Takeda S, et al. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. J Lab Clin Med 2000; 135:353-359.
127. Kobayashi N, Nishikimi T, Horinaka S, Ishimitsu T, Matsuoka H. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats. Atherosclerosis 2001; 156:255-265.
128. Nagata K, Somura F, Obata K, Odashima M, Izawa H, Ichihara S, et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 2002; 40:168-174.
129. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004; 143:41-51.
130. Yamazaki T, Komuro I, Yazaki Y. Role of the renin-angiotensin system in cardiac hypertrophy. Am J Cardiol 1999; 83:53H-57H.
131. Lindholm LH, Dahlof B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362:619-620.
132. Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 2005; [epub ahead of print].
133. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
134. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989; 299:1127-1131.
135. Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Goteborg, Sweden. Eur Heart J 1997; 18:754-761.
136. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Heart Lung Transplant 2002; 21:189-203.
137. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-1560.
138. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752-760.
139. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
140. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16:544-548.
141. Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press 2001; 10:83-91.
142. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34:1699-1703.
143. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
144. Popvic JR, Kozak LJ. National hospital discharge survey: annual summary 1998. Washington, DC: Government Printing Office, DHHS Publications; 2000. Series 13, No 148.(PHS 2000-179).
145. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273:1450-1456.
146. Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20:1182-1190.
147. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
148. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
149. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
150. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004; 17: 16S-20S.
151. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
152. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022-2031.
153. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
154. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
155. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
156. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
157. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473.
158. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004; 53:989-997.
159. Ko SH, Kwon HS, Kim SR, Moon SD, Ahn YB, Song KH, et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun 2004; 316:114-122.
160. de Pablos PL, Martinez J, Aguilar J, Rodriguez F, Murado P, Macias A. Effects of losartan on blood pressure, microalbuminuria, insulin sensitivity, and lipid profile [abstract]. Atherosclerosis 1997; 134:139.
161. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26:1402-1407.
162. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, et al. Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: the RENAAL study economic evaluation. Diabetes Care 2003; 26:683-687.
163. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003; 18:2059-2066.
164. Jonsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlof B. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens 2005; 23:1425-1431.
165. Jonsson L, Gerth W, Fastbom J. The potential economic consequences of cognitive improvement with losartan. Blood Press 2002; 11:46-52.
166. ACE Inhibitors in Diabetic Nephropathy Trialists' group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134:370-379.
167. Brenner BM, Cooper ME, Zeeuw DD, Grunfeld JP, Keane WF, Kurokawa K, et al. The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000; 1:328-335.
168. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
169. Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med 2000; 160:1585-1594.
170. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35:695-707.
171. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703-713.
172. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20:1576-1581.
173. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641-1650.
174. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
175. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13:47-53.
176. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46:1182-1188.
177. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581.
178. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35:1155-1165.
179. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713-720.
180. 80 Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328:495-500.
181. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45:S150-S155.
182. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329:828-832.
183. Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprlL (DETAIL) study. Acta Diabetol 2005; 42(Suppl 1):S42-S49.